
Jan P. Nicolay, MD, PhD, explains how early single-cell data suggest mogamulizumab resistance switches on anti-apoptotic survival proteins.

Jan P. Nicolay, MD, PhD, explains how early single-cell data suggest mogamulizumab resistance switches on anti-apoptotic survival proteins.

Jan P. Nicolay, MD, PhD, explains why some patients stop responding to mogamulizumab comes down to the tumor shedding its target and new survival mechanisms the cell switches on.